Understanding the role of Prostaglandin D2 in chronic skin allergies
Official title: Functional Characterization of Prostaglandin D2 in Chronic Spontaneous Urticaria
Funded at Johns Hopkins University · NIH-10660944 · Data updated 2026-11-12
This study is looking into how a substance called Prostaglandin D2 might be causing allergic reactions in people with chronic spontaneous urticaria (CSU), which affects about 1 in 100 people, to help find new treatment options for those who aren't getting better with current medicines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 15, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $196,400 |
| NIH project number | 5K23AI139394-05 |
| Project ID | NIH-10660944 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic spontaneous urticaria who have not found relief with current FDA-approved treatments.
✕Less likely to help
Patients with acute urticaria or those whose symptoms are linked to identifiable triggers may not benefit from this research.
What this research studies
This research investigates how Prostaglandin D2 (PGD2) contributes to chronic spontaneous urticaria (CSU), a condition affecting about 1% of the population. The study aims to uncover the mechanisms by which PGD2 activates immune cells and skin cells, leading to allergic reactions. By analyzing skin biopsies from patients with CSU, the research will explore the inflammatory processes involved and seek to identify potential new treatment targets for those who do not respond to existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for patients suffering from chronic spontaneous urticaria.
How similar studies have gone: Previous research has shown promising results in understanding the role of inflammatory mediators in allergic conditions, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Oliver, Eric T — Johns Hopkins University
- Study coordinator: Oliver, Eric T
Related research
Other NIH-funded projects on the same topics.
-
Remibrutinib and omalizumab-based treatment approach for adults with chronic spontaneous urticaria not well controlled by antihistamines
This trial tests a sequencing plan using remibrutinib and omalizumab to see if it helps adults with chronic spontaneous urticaria that isn’t well controlled by second-generation antihistamines.
-
BBT001 in adults with chronic spontaneous urticaria
This trial tests whether BBT001 given by IV is safe and can help reduce urticaria in adults who have chronic spontaneous hives.
-
Remibrutinib in real-world care for Chronic Spontaneous Urticaria in Germany
This study looks at how well and how safely remibrutinib works for adults with chronic spontaneous urticaria in real clinical practice after doctors decide to switch or escalate treatment.
-
Testing single and multiple oral doses of EDP-978 in healthy adults
This study will test how safe and tolerable single and multiple oral doses of EDP-978 are in healthy adults and will measure how the body absorbs and responds to the drug.
-
Remibrutinib for adults with chronic spontaneous urticaria in routine care
This prospective US study will see if remibrutinib helps adults with chronic spontaneous urticaria in real-world clinical practice using patient-reported outcome questionnaires.
-
JYB1904 Injection for Chronic Spontaneous Urticaria in Adults
This trial tests whether JYB1904 injections help adults with chronic spontaneous hives that aren’t well controlled by standard antihistamines.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.